期刊
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
卷 331, 期 1, 页码 178-185出版社
AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/jpet.109.157107
关键词
-
资金
- National Institutes of Health National Institute on Aging
We had proposed previously a novel combination of beta 2-adrenoreceptor (AR) agonist and beta 1-AR blocker that in the rat model of postmyocardial infarction (MI) dilated cardiomyopathy exceeds the therapeutic effectiveness of either monotherapy. In the present study, we compared that treatment with a combination of beta 1-AR blocker and angiotensin-converting enzyme inhibitor (ACEi), a current standard chronic heart failure (CHF) therapy. Two weeks after coronary artery ligation, rats were divided into groups of similar average MI size, measured by echocardiography, and the following 12-month treatments were initiated: fenoterol (250 mu g/kg/day), a beta 2-AR agonist, plus metoprolol (100 mg/kg/day), a beta 1-AR blocker (beta 1-beta 2+); metoprolol plus enalapril (20 mg/kg/day), an ACEi (beta 1-ACEi); and a combination of all three drugs (beta 1-beta 2+ACEi). These treatment groups were compared with each other and with nontreated (nT) and sham groups. The 12-month mortality was significantly reduced in all treatment groups (44% in beta 1-beta 2+, 56% in beta 1-beta 2+ACEi, 59% in beta 1-ACEi versus 81% in nT). Bimonthly echocardiography revealed significant attenuation of the left ventricular (LV) chamber remodeling, LV functional deterioration, and MI expansion in all three treatment groups, but effects were significantly more pronounced when treatment included a beta 2-AR agonist. The results indicated that a combination of beta 1-AR blocker and beta 2-AR agonist is equipotent to a combination of beta 1-AR blocker and ACEi in the treatment of CHF in rats, with the respect to mortality, and exceeds the latter with respect to cardiac remodeling and MI expansion. Thus, this novel therapeutic regimen for CHF warrants detailed clinical investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据